Author:
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization, 2006. WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 81: 445– 452.
-
2.
Peltola H, 2001. Burden of meningitis and other severe bacterial infections of children in Africa: implications for prevention. Clin Infect Dis 32: 64– 75.
-
3.
Levine OS, Lagos R, Munoz A, Villaroel J, Alvarez AM, Abrego P, Levine MM, 1999. Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J 18: 1060– 1064.
-
4.
Bradshaw MW, Schneerson R, Parke JC Jr, Robbins JB, 1971. Bacterial antigens cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b. Lancet 1: 1095– 1096.
-
5.
Robbins JB, Schneerson R, Argaman M, Handzel ZT, 1973. Haemophilus influenzae type b: disease and immunity in humans. Ann Intern Med 78: 259– 269.
-
6.
Kelly DF, Moxon ER, Yu LM, Pollard AJ, 2009. Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United Kingdom. Clin Vaccine Immunol 16: 246– 252.
-
7.
Pollard AJ, Perrett KP, Beverley PC, 2009. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 9: 213– 220.
-
8.
Schlesinger Y, Granoff DM, 1992. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 267: 1489– 1494.
-
9.
Campbell JD, Lagos R, Levine MM, Losonsky GA, 2002. Standard and alternative regimens of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infants. Pediatr Infect Dis J 21: 822– 826.
-
10.
Goldblatt D, Vaz AR, Miller E, 1998. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 177: 1112– 1115.
-
11.
Watt JP, Levine OS, Santosham M, 2003. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22–25, 2002. J Pediatr 143: S163– S187.
-
12.
Granoff DM, Anderson EL, Osterholm MT, Holmes SJ, McHugh JE, Belshe RB, Medley F, Murphy TV, 1992. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 121: 187– 194.
-
13.
Campagne G, Garba A, Schuchat A, Boulanger D, Plikaytis BD, Ousseini M, Chippaux JP, 1998. Response to conjugate Haemophilus influenzae B vaccine among infants in Niamey, Niger. Am J Trop Med Hyg 59: 837– 842.
-
14.
Adegbola RA, Secka O, Lahai G, Lloyd-Evans N, Njie A, Usen S, Oluwalana C, Obaro S, Weber M, Corrah T, Mulholland K, McAdam K, Greenwood B, Milligan PJ, 2005. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 366: 144– 150.
-
15.
Sow SO, Tapia MD, Diallo S, Keita MM, Sylla M, Onwuchekwa U, Pasetti MF, Kotloff KL, Levine MM, 2009. Haemophilus influenzae type b conjugate vaccine introduction in Mali: impact on disease burden and serologic correlate of protection. Am J Trop Med Hyg 80: 1033– 1038.
-
16.
Cisse MF, Breugelmans JG, Ba M, Diop MB, Faye PC, Mhlanga B, Mueller JE, Koffi D, Gessner BD, 2010. The elimination of Haemophilus influenzae type b meningitis following conjugate vaccine introduction in Senegal. Pediatr Infect Dis J 29: 499– 503.
-
17.
Fernandez J, Levine OS, Sanchez J, Balter S, LaClaire L, Feris J, Romero-Steiner S, 2000. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. J Infect Dis 182: 1553– 1556.
-
18.
Kayhty H, Peltola H, Karanko V, Makela PH, 1983. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 147: 1100.
-
19.
Khatami A, Snape MD, John T, Westcar S, Klinger C, Rollinson L, Boutriau D, Mesaros N, Wysocki J, Galaj A, Yu LM, Pollard AJ, 2011. Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial. Pediatr Infect Dis J 30: 197– 202.
-
20.
Eskola J, Kayhty H, Takala AK, Peltola H, Ronnberg PR, Kela E, Pekkanen E, McVerry PH, Makela PH, 1990. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 323: 1381– 1387.
-
21.
Slack MH, Schapira D, Thwaites RJ, Burrage M, Southern J, Goldblatt D, Miller E, 2004. Responses to a fourth dose of Haemophilus influenzae type B conjugate vaccine in early life. Arch Dis Child Fetal Neonatal Ed 89: F269– F271.
-
22.
Ladhani S, Heath PT, Ramsay ME, Slack MP, Kibwana E, Pollard AJ, Booy R, 2009. Long-term immunological follow-up of children with Haemophilus influenzae serotype b vaccine failure in the United Kingdom. Clin Infect Dis 49: 372– 380.
-
23.
Habermehl P, Leroux-Roels G, Sanger R, Machler G, Boutriau D, 2010. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12–18 months of age. Hum Vaccin 6: 640– 651.
-
24.
Ladhani S, Heath PT, Slack MP, McIntyre PB, Diez-Domingo J, Campos J, Dagan R, Ramsay ME, 2010. Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes. Clin Microbiol Infect 16: 948– 954.
-
25.
Madhi SA, Kuwanda L, Saarinen L, Cutland C, Mothupi R, Kayhty H, Klugman KP, 2005. Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine 23: 5517– 5525.
-
26.
Mulholland EK, Hoestermann A, Ward JI, Maine N, Ethevenaux C, Greenwood BM, 1996. The use of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine mixed with diphtheria-tetanus-pertussis vaccine in Gambian infants. Vaccine 14: 905– 909.
-
27.
Madore DV, Johnson CL, Phipps DC, Myers MG, Eby R, Smith DH, 1990. Safety and immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in infants aged 15 to 23 months. Pediatrics 86: 527– 534.
-
28.
Mulholland EK, Byass P, Campbell H, Fritzell B, Greenwood AM, Todd J, Greenwood BM, 1994. The immunogenicity and safety of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in Gambian infants. Ann Trop Paediatr 14: 183– 188.
-
29.
Obaro SK, Enwere GC, Deloria M, Jaffar S, Goldblatt D, Brainsby K, Hallander H, McInnes P, Greenwood BM, McAdam KP, 2002. Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine. Pediatr Infect Dis J 21: 940– 947.
-
30.
Punjabi NH, Richie EL, Simanjuntak CH, Harjanto SJ, Wangsasaputra F, Arjoso S, Rofiq A, Prijanto M, Julitasari, Yela U, Herzog C, Cryz SJ, 2006. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants. Vaccine 24: 1776– 1785.
-
31.
Hirve S, Bavdekar A, Juvekar S, Agarwal D, Barde P, Mangrule S, Patwardhan M, Pandit A, Kulkarni PS, 2011. A comparative study to evaluate the safety and immunogenicity of two lots of Haemophilus influenzae type-B conjugate vaccine manufactured at different scales. Vaccine 29: 5363– 5367.
-
32.
Panpitpat C, Thisyakorn U, Chotpitayasunondh T, Furer E, Que JU, Hasler T, Cryz SJ Jr, 2000. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine. Bull World Health Organ 78: 364– 371.
-
33.
Espinoza F, Tregnaghi M, Gentile A, Abarca K, Casellas J, Collard A, Lefevre I, Jacquet JM, 2010. Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial. BMC Infect Dis 10: 297.
-
34.
Lee CY, Thipphawong J, Huang LM, Lee PI, Chiu HH, Lin W, Debois H, Harrison D, Xie F, Barreto L, 1999. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. Pediatrics 103: 25– 30.
-
35.
Sow SO, Diallo S, Campbell JD, Tapia MD, Keita T, Keita MM, Murray P, Kotloff KL, Levine MM, 2005. Burden of invasive disease caused by Haemophilus influenzae type b in Bamako, Mali: impetus for routine infant immunization with conjugate vaccine. Pediatr Infect Dis J 24: 533– 537.
-
36.
United Nations Children's Fund, 2011. State of the World's Children: Adolescence, an Age of Opportunity. Tinton Falls, NJ: Hatteras Press, 1– 128.
-
37.
Booy R, Hodgson S, Carpenter L, Mayon-White RT, Slack MP, Macfarlane JA, Haworth EA, Kiddle M, Shribman S, Roberts JS, 1994. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 344: 362– 366.
-
38.
Hargreaves RM, Slack MP, Howard AJ, Anderson E, Ramsay ME, 1996. Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme. BMJ 312: 160– 161.
-
39.
Slack MP, Azzopardi HJ, Hargreaves RM, Ramsay ME, 1998. Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccines. Pediatr Infect Dis J 17: S204– S207.
-
40.
Booy R, Heath PT, Slack MP, Begg N, Moxon ER, 1997. Vaccine failures after primary immunization with Haemophilus influenzae type-b conjugate vaccine without booster [see comments]. Lancet 349: 1197– 1202.
-
41.
Trotter CL, Ramsay ME, Slack MP, 2003. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health 6: 55– 58.
-
42.
Ladhani S, Slack MP, Heys M, White J, Ramsay ME, 2008. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child 93: 665– 669.
-
43.
Heath PT, Booy R, Azzopardi HJ, Slack MP, Bowen-Morris J, Griffiths H, Ramsay ME, Deeks JJ, Moxon ER, 2000. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 284: 2334– 2340.
-
44.
Hoppenbrouwers K, Lagos R, Swennen B, Ethevenaux C, Knops J, Levine MM, Desmyter J, 1998. Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. Vaccine 16: 921– 927.
-
45.
Michaels RH, Norden CW, 1977. Pharyngeal colonization with Haemophilus influenzae type b: a longitudinal study of families with a child with meningitis or epiglottitis due to H. influenzae type b. J Infect Dis 136: 222– 228.
-
46.
Hall DB, Lum MK, Knutson LR, Heyward WL, Ward JI, 1987. Pharyngeal carriage and acquisition of anticapsular antibody to Haemophilus influenzae type b in a high-risk population in southwestern Alaska. Am J Epidemiol 126: 1190– 1197.
-
47.
Schneerson R, Bradshaw M, Whisnant JK, Myerowitz RL, Parke JC Jr, Robbins JB, 1972. An Escherichia coli antigen cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b: occurrence among known serotypes, and immunochemical and biologic properties of E. coli antisera toward H. influenzae type b. J Immunol 108: 1551– 1562.
-
48.
Myerowitz RL, Gordon RE, Robbins JB, 1973. Polysaccharides of the genus Bacillus cross-reactive with the capsular polysaccharides of Diplococcus pneumoniae type 3, Haemophilus influenzae type b, and Neisseria meningitidis group A. Infect Immun 8: 896– 900.
-
49.
Handzel ZT, Argaman M, Parke JC Jr, Schneerson R, Robbins JB, 1975. Heteroimmunization to the capsular polysaccharide of Haemophilus influenzae type b induced by enteric cross-reacting bacteria. Infect Immun 11: 1045– 1052.
-
50.
Schneerson R, Robbins JB, 1975. Induction of serum Haemophilus influenzae type b capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5. N Engl J Med 292: 1093– 1096.
-
51.
Southern J, McVernon J, Gelb D, Andrews N, Morris R, Crowley-Luke A, Goldblatt D, Miller E, 2007. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. Clin Vaccine Immunol 14: 1328– 1333.
-
52.
Adegbola RA, Mulholland EK, Secka O, Jaffar S, Greenwood BM, 1998. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J Infect Dis 177: 1758– 1761.
-
53.
Heath PT, McVernon J, 2002. The UK Hib vaccine experience. Arch Dis Child 86: 396– 399.
-
54.
Howie SR, Antonio M, Akisanya A, Sambou S, Hakeem I, Secka O, Adegbola RA, 2007. Re-emergence of Haemophilus influenzae type b (Hib) disease in The Gambia following successful elimination with conjugate Hib vaccine. Vaccine 25: 6305– 6309.
Naturally Acquired and Conjugate Vaccine-Induced Antibody to Haemophilus influenzae Type b (Hib) Polysaccharide in Malian Children: Serological Assessment of the Hib Immunization Program in Mali
Julia Hutter
Julia Hutter
Center for Vaccine Development and the Departments of Pediatrics and Medicine, University of Maryland School of Medicine, Baltimore, Maryland; Centre pour le Développement des Vaccins, Mali, Bamako, Mali
Search for other papers by Julia Hutter in
Current site
Google Scholar
PubMed
Search for other papers by Julia Hutter in
Current site
Google Scholar
PubMed
Marcela F. Pasetti
Marcela F. Pasetti
Center for Vaccine Development and the Departments of Pediatrics and Medicine, University of Maryland School of Medicine, Baltimore, Maryland; Centre pour le Développement des Vaccins, Mali, Bamako, Mali
Search for other papers by Marcela F. Pasetti in
Current site
Google Scholar
PubMed
Search for other papers by Marcela F. Pasetti in
Current site
Google Scholar
PubMed
Doh Sanogo
Doh Sanogo
Center for Vaccine Development and the Departments of Pediatrics and Medicine, University of Maryland School of Medicine, Baltimore, Maryland; Centre pour le Développement des Vaccins, Mali, Bamako, Mali
Search for other papers by Doh Sanogo in
Current site
Google Scholar
PubMed
Search for other papers by Doh Sanogo in
Current site
Google Scholar
PubMed
Milagritos D. Tapia
Milagritos D. Tapia
Center for Vaccine Development and the Departments of Pediatrics and Medicine, University of Maryland School of Medicine, Baltimore, Maryland; Centre pour le Développement des Vaccins, Mali, Bamako, Mali
Search for other papers by Milagritos D. Tapia in
Current site
Google Scholar
PubMed
Search for other papers by Milagritos D. Tapia in
Current site
Google Scholar
PubMed
Samba O. Sow
Samba O. Sow
Center for Vaccine Development and the Departments of Pediatrics and Medicine, University of Maryland School of Medicine, Baltimore, Maryland; Centre pour le Développement des Vaccins, Mali, Bamako, Mali
Search for other papers by Samba O. Sow in
Current site
Google Scholar
PubMed
Search for other papers by Samba O. Sow in
Current site
Google Scholar
PubMed
Myron M. Levine
Myron M. Levine
Center for Vaccine Development and the Departments of Pediatrics and Medicine, University of Maryland School of Medicine, Baltimore, Maryland; Centre pour le Développement des Vaccins, Mali, Bamako, Mali
Search for other papers by Myron M. Levine in
Current site
Google Scholar
PubMed
Search for other papers by Myron M. Levine in
Current site
Google Scholar
PubMed
Haemophilus influenzae type b (Hib) conjugate vaccine for infants (6, 10, and 14 weeks of age) was introduced into the Malian Expanded Program on Immunization in July 2005, to diminish invasive Hib disease in young children. Antibodies to Hib capsular polysaccharide (PRP) were measured in infants and toddlers from an area already served by the Hib immunization program (Bamako) and in unimmunized children of the same age in a district (Kangaba) where Hib immunization had not yet begun. Among vaccinated Bamako children 6–23 months of age, 77–93% exhibited PRP titers ≥ 1.0 μg/mL, indicating long-term protection, versus only 10–23% of Kangaba children of that age. High PRP antibody titers in immunized children persisted through 2 years of age. Moreover, ∼50% of Bamako children exhibited anti-PRP titers ≥ 5.0 μg/mL; a level that impedes Hib upper respiratory carriage, and may thereby diminish the Hib transmission to the unimmunized susceptible population (i.e., providing indirect protection).
Author Notes
Financial Support: Grant from the Bill and Melinda Gates Foundation to Myron M. Levine.
Authors' addresses: Julia Hutter, Marcela F. Pasetti, Milagritos D. Tapia, and Myron M. Levine, University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, MD, E-mails: jthutter@gmail.com, mpasetti@medicine.umaryland.edu, mtapia@medicine.umaryland.edu, and mlevine@medicine.umaryland.edu. Doh Sanogo and Samba O. Sow, Ministry of Health, Centre pour le Développement des Vaccins – Mali, Ex-Institut Marchoux, Bamako, Mali, E-mails: sanogodoh@yahoo.fr and ssow@medicine.umaryland.edu.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization, 2006. WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 81: 445– 452.
-
2.
Peltola H, 2001. Burden of meningitis and other severe bacterial infections of children in Africa: implications for prevention. Clin Infect Dis 32: 64– 75.
-
3.
Levine OS, Lagos R, Munoz A, Villaroel J, Alvarez AM, Abrego P, Levine MM, 1999. Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J 18: 1060– 1064.
-
4.
Bradshaw MW, Schneerson R, Parke JC Jr, Robbins JB, 1971. Bacterial antigens cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b. Lancet 1: 1095– 1096.
-
5.
Robbins JB, Schneerson R, Argaman M, Handzel ZT, 1973. Haemophilus influenzae type b: disease and immunity in humans. Ann Intern Med 78: 259– 269.
-
6.
Kelly DF, Moxon ER, Yu LM, Pollard AJ, 2009. Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United Kingdom. Clin Vaccine Immunol 16: 246– 252.
-
7.
Pollard AJ, Perrett KP, Beverley PC, 2009. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 9: 213– 220.
-
8.
Schlesinger Y, Granoff DM, 1992. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 267: 1489– 1494.
-
9.
Campbell JD, Lagos R, Levine MM, Losonsky GA, 2002. Standard and alternative regimens of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infants. Pediatr Infect Dis J 21: 822– 826.
-
10.
Goldblatt D, Vaz AR, Miller E, 1998. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 177: 1112– 1115.
-
11.
Watt JP, Levine OS, Santosham M, 2003. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22–25, 2002. J Pediatr 143: S163– S187.
-
12.
Granoff DM, Anderson EL, Osterholm MT, Holmes SJ, McHugh JE, Belshe RB, Medley F, Murphy TV, 1992. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 121: 187– 194.
-
13.
Campagne G, Garba A, Schuchat A, Boulanger D, Plikaytis BD, Ousseini M, Chippaux JP, 1998. Response to conjugate Haemophilus influenzae B vaccine among infants in Niamey, Niger. Am J Trop Med Hyg 59: 837– 842.
-
14.
Adegbola RA, Secka O, Lahai G, Lloyd-Evans N, Njie A, Usen S, Oluwalana C, Obaro S, Weber M, Corrah T, Mulholland K, McAdam K, Greenwood B, Milligan PJ, 2005. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 366: 144– 150.
-
15.
Sow SO, Tapia MD, Diallo S, Keita MM, Sylla M, Onwuchekwa U, Pasetti MF, Kotloff KL, Levine MM, 2009. Haemophilus influenzae type b conjugate vaccine introduction in Mali: impact on disease burden and serologic correlate of protection. Am J Trop Med Hyg 80: 1033– 1038.
-
16.
Cisse MF, Breugelmans JG, Ba M, Diop MB, Faye PC, Mhlanga B, Mueller JE, Koffi D, Gessner BD, 2010. The elimination of Haemophilus influenzae type b meningitis following conjugate vaccine introduction in Senegal. Pediatr Infect Dis J 29: 499– 503.
-
17.
Fernandez J, Levine OS, Sanchez J, Balter S, LaClaire L, Feris J, Romero-Steiner S, 2000. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. J Infect Dis 182: 1553– 1556.
-
18.
Kayhty H, Peltola H, Karanko V, Makela PH, 1983. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 147: 1100.
-
19.
Khatami A, Snape MD, John T, Westcar S, Klinger C, Rollinson L, Boutriau D, Mesaros N, Wysocki J, Galaj A, Yu LM, Pollard AJ, 2011. Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial. Pediatr Infect Dis J 30: 197– 202.
-
20.
Eskola J, Kayhty H, Takala AK, Peltola H, Ronnberg PR, Kela E, Pekkanen E, McVerry PH, Makela PH, 1990. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 323: 1381– 1387.
-
21.
Slack MH, Schapira D, Thwaites RJ, Burrage M, Southern J, Goldblatt D, Miller E, 2004. Responses to a fourth dose of Haemophilus influenzae type B conjugate vaccine in early life. Arch Dis Child Fetal Neonatal Ed 89: F269– F271.
-
22.
Ladhani S, Heath PT, Ramsay ME, Slack MP, Kibwana E, Pollard AJ, Booy R, 2009. Long-term immunological follow-up of children with Haemophilus influenzae serotype b vaccine failure in the United Kingdom. Clin Infect Dis 49: 372– 380.
-
23.
Habermehl P, Leroux-Roels G, Sanger R, Machler G, Boutriau D, 2010. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12–18 months of age. Hum Vaccin 6: 640– 651.
-
24.
Ladhani S, Heath PT, Slack MP, McIntyre PB, Diez-Domingo J, Campos J, Dagan R, Ramsay ME, 2010. Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes. Clin Microbiol Infect 16: 948– 954.
-
25.
Madhi SA, Kuwanda L, Saarinen L, Cutland C, Mothupi R, Kayhty H, Klugman KP, 2005. Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine 23: 5517– 5525.
-
26.
Mulholland EK, Hoestermann A, Ward JI, Maine N, Ethevenaux C, Greenwood BM, 1996. The use of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine mixed with diphtheria-tetanus-pertussis vaccine in Gambian infants. Vaccine 14: 905– 909.
-
27.
Madore DV, Johnson CL, Phipps DC, Myers MG, Eby R, Smith DH, 1990. Safety and immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in infants aged 15 to 23 months. Pediatrics 86: 527– 534.
-
28.
Mulholland EK, Byass P, Campbell H, Fritzell B, Greenwood AM, Todd J, Greenwood BM, 1994. The immunogenicity and safety of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in Gambian infants. Ann Trop Paediatr 14: 183– 188.
-
29.
Obaro SK, Enwere GC, Deloria M, Jaffar S, Goldblatt D, Brainsby K, Hallander H, McInnes P, Greenwood BM, McAdam KP, 2002. Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine. Pediatr Infect Dis J 21: 940– 947.
-
30.
Punjabi NH, Richie EL, Simanjuntak CH, Harjanto SJ, Wangsasaputra F, Arjoso S, Rofiq A, Prijanto M, Julitasari, Yela U, Herzog C, Cryz SJ, 2006. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants. Vaccine 24: 1776– 1785.
-
31.
Hirve S, Bavdekar A, Juvekar S, Agarwal D, Barde P, Mangrule S, Patwardhan M, Pandit A, Kulkarni PS, 2011. A comparative study to evaluate the safety and immunogenicity of two lots of Haemophilus influenzae type-B conjugate vaccine manufactured at different scales. Vaccine 29: 5363– 5367.
-
32.
Panpitpat C, Thisyakorn U, Chotpitayasunondh T, Furer E, Que JU, Hasler T, Cryz SJ Jr, 2000. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine. Bull World Health Organ 78: 364– 371.
-
33.
Espinoza F, Tregnaghi M, Gentile A, Abarca K, Casellas J, Collard A, Lefevre I, Jacquet JM, 2010. Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial. BMC Infect Dis 10: 297.
-
34.
Lee CY, Thipphawong J, Huang LM, Lee PI, Chiu HH, Lin W, Debois H, Harrison D, Xie F, Barreto L, 1999. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. Pediatrics 103: 25– 30.
-
35.
Sow SO, Diallo S, Campbell JD, Tapia MD, Keita T, Keita MM, Murray P, Kotloff KL, Levine MM, 2005. Burden of invasive disease caused by Haemophilus influenzae type b in Bamako, Mali: impetus for routine infant immunization with conjugate vaccine. Pediatr Infect Dis J 24: 533– 537.
-
36.
United Nations Children's Fund, 2011. State of the World's Children: Adolescence, an Age of Opportunity. Tinton Falls, NJ: Hatteras Press, 1– 128.
-
37.
Booy R, Hodgson S, Carpenter L, Mayon-White RT, Slack MP, Macfarlane JA, Haworth EA, Kiddle M, Shribman S, Roberts JS, 1994. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 344: 362– 366.
-
38.
Hargreaves RM, Slack MP, Howard AJ, Anderson E, Ramsay ME, 1996. Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme. BMJ 312: 160– 161.
-
39.
Slack MP, Azzopardi HJ, Hargreaves RM, Ramsay ME, 1998. Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccines. Pediatr Infect Dis J 17: S204– S207.
-
40.
Booy R, Heath PT, Slack MP, Begg N, Moxon ER, 1997. Vaccine failures after primary immunization with Haemophilus influenzae type-b conjugate vaccine without booster [see comments]. Lancet 349: 1197– 1202.
-
41.
Trotter CL, Ramsay ME, Slack MP, 2003. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health 6: 55– 58.
-
42.
Ladhani S, Slack MP, Heys M, White J, Ramsay ME, 2008. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child 93: 665– 669.
-
43.
Heath PT, Booy R, Azzopardi HJ, Slack MP, Bowen-Morris J, Griffiths H, Ramsay ME, Deeks JJ, Moxon ER, 2000. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 284: 2334– 2340.
-
44.
Hoppenbrouwers K, Lagos R, Swennen B, Ethevenaux C, Knops J, Levine MM, Desmyter J, 1998. Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. Vaccine 16: 921– 927.
-
45.
Michaels RH, Norden CW, 1977. Pharyngeal colonization with Haemophilus influenzae type b: a longitudinal study of families with a child with meningitis or epiglottitis due to H. influenzae type b. J Infect Dis 136: 222– 228.
-
46.
Hall DB, Lum MK, Knutson LR, Heyward WL, Ward JI, 1987. Pharyngeal carriage and acquisition of anticapsular antibody to Haemophilus influenzae type b in a high-risk population in southwestern Alaska. Am J Epidemiol 126: 1190– 1197.
-
47.
Schneerson R, Bradshaw M, Whisnant JK, Myerowitz RL, Parke JC Jr, Robbins JB, 1972. An Escherichia coli antigen cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b: occurrence among known serotypes, and immunochemical and biologic properties of E. coli antisera toward H. influenzae type b. J Immunol 108: 1551– 1562.
-
48.
Myerowitz RL, Gordon RE, Robbins JB, 1973. Polysaccharides of the genus Bacillus cross-reactive with the capsular polysaccharides of Diplococcus pneumoniae type 3, Haemophilus influenzae type b, and Neisseria meningitidis group A. Infect Immun 8: 896– 900.
-
49.
Handzel ZT, Argaman M, Parke JC Jr, Schneerson R, Robbins JB, 1975. Heteroimmunization to the capsular polysaccharide of Haemophilus influenzae type b induced by enteric cross-reacting bacteria. Infect Immun 11: 1045– 1052.
-
50.
Schneerson R, Robbins JB, 1975. Induction of serum Haemophilus influenzae type b capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5. N Engl J Med 292: 1093– 1096.
-
51.
Southern J, McVernon J, Gelb D, Andrews N, Morris R, Crowley-Luke A, Goldblatt D, Miller E, 2007. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. Clin Vaccine Immunol 14: 1328– 1333.
-
52.
Adegbola RA, Mulholland EK, Secka O, Jaffar S, Greenwood BM, 1998. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J Infect Dis 177: 1758– 1761.
-
53.
Heath PT, McVernon J, 2002. The UK Hib vaccine experience. Arch Dis Child 86: 396– 399.
-
54.
Howie SR, Antonio M, Akisanya A, Sambou S, Hakeem I, Secka O, Adegbola RA, 2007. Re-emergence of Haemophilus influenzae type b (Hib) disease in The Gambia following successful elimination with conjugate Hib vaccine. Vaccine 25: 6305– 6309.